Initially developed for atopic dermatitis, Enveda's lead asset ENV-294 is now showing promise in treating asthma.

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.

However, biologics like Dupixent (dupilumab) have paved the way for ... With its innovative mechanism of action and established success in asthma, Fasenra could address critical safety and ...

Patients treated with dupilumab have shown significant improvements ... based on individual patient profiles and the underlying mechanisms of their disease. Chronic Rhinosinusitis (CRS): A long ...

Ebglyss, the third biologic targeting IL-13 for atopic dermatitis, follows Dupixent (dupilumab) and Adbry/Adtralza (tralokinumab ... on healthy cells making it an attractive target. This mechanism ...

EBGLYSS™, the third biologic targeting IL-13 for atopic dermatitis, follows DUPIXENT® (dupilumab ... cells making it an attractive target. This mechanism positions IMDELLTRA as a potential ...

At that time Sanofi was cruising towards an important FDA approval for its Dupixent (dupilumab ... which has a different mechanism of action focused on IL-4. Incyte is also planning a US filing ...

The company bagged FDA approval for first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor Ohtuvayre (ensifentrine) last June, becoming the first inhaled product with a novel mechanism of ...

Dupilumab, by binding to IL-4Rα ... The previously mentioned molecular mechanisms endorse the rationale for the development of biologic drugs with targets shared by multiple diseases. Despite common ...

Dupixent, or Dupilumab, is an FDA-approved monoclonal antibody for the treatment of eosinophilic esophagitis, or EoE, due to esophageal inflammation. It works on the mechanism of inhibiting IL-4 and ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached ... pharmaceutical companies are investigating agents with different mechanisms of action to ...